Musculo-skeletal disorder
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
Loci Orthopaedics announces €12.8m series A financing
July 17, 2024Business Services Financing, Musculo-skeletal disorder, investment, loci orthopaedics
Loci Orthopaedics has announced the successful closing of an oversubscribed €12.8m series A financing, which was led by new investors …
Abcuro completes enrolment for phase 2/3 IBM treatment trial
June 26, 2024Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart
Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …
Sarepta Therapeutics gains expanded FDA approval for DMD treatment
June 21, 2024Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics
Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …
Pfizer shares update on DMD gene therapy clinical trial
June 13, 2024Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy
Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
June 11, 2024Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera
Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
May 14, 2024Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …
FDA approves Sandoz’s denosumab biosimilars
March 6, 2024Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
Regenxbio announces initial efficacy data from phase 1/2 AFFINITY DUCHENNE trial
March 6, 2024Research and Development Duchenne Muscular Dystrophy, Musculo-skeletal disorder, Regenxbio, clinical trial
Regenxbio has announced additional interim safety data from its phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne …
Novartis shares new data for Zolgensma in children with SMA
March 5, 2024Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
Renovos Biologics gains FDA Breakthrough Device Designation for Renovite
January 4, 2024Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation
Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …
FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment
December 14, 2023Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis
Kyverna Therapeutics has announced that it has gained fast track designation from the US Food and Drug Administration (FDA) for …
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …
NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment
September 27, 2023Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy
NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …
Latest content
